Publications

1. Su E, Valencia NMS, Le J, Liu E, Wilson JL. Across preclinical and clinical platforms, approved and investigational psychiatric drugs share pathways and associate with similar molecular functions.. Frontiers in drug discovery, 2026.
2. Alidoost M, Le A, Wilson JL. Curated and Structure-Based Drug-Target Interactions Improve Underprediction of Drug Side Effects in Network Models.. Journal of chemical information and modeling, 2026.
3. Bozich ER, Guo X, Wilson JL, Hoffmann A. A computational workflow for assessing drug effects on temporal signaling dynamics reveals robustness in stimulus-specific NFκB signaling.. PLoS computational biology, 2025.
4. Alidoost M, Huang JY, Dermentzaki G, Blazier AS, Gaglia G, Hammond TR, Frau F, McCorry MC, Ofengeim D, Wilson JL. Uncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis and Neurological Diseases Using Real-World Data.. Clinical pharmacology and therapeutics, 2025.
5. Alidoost M, Wilson JL. Preclinical side effect prediction through pathway engineering of protein interaction network models.. CPT: pharmacometrics & systems pharmacology, 2024.
6. Liu HJ, Wilson JL. Drug target, class level, and PathFX pathway information share utility for machine learning prediction of common drug-induced side effects.. Frontiers in drug safety and regulation, 2023.
7. Wilson JL, Steinberg E, Racz R, Altman RB, Shah N, Grimes K. A network paradigm predicts drug synergistic effects using downstream protein-protein interactions.. CPT: pharmacometrics & systems pharmacology, 2022.
8. Wilson JL, Gravina A, Grimes K. From random to predictive: a context-specific interaction framework improves selection of drug protein-protein interactions for unknown drug pathways.. Integrative biology : quantitative biosciences from nano to macro, 2022.